Navigation Links
Anti-cancer gene discovered: Perspective for therapy

Starting with the tiny fruit fly, and then moving into mouse and human patients, researchers at VIB connected to the Center for Human Genetics (K.U. Leuven) showed that the same gene suppresses cancer in all three. Reciprocally, switching off the gene leads to cancer. The scientists think there is a good chance that the gene can be switched on again with a drug. They report their findings in the reputed scientific journal PLoS Biology.

Specialized cells

All of us begin our lives as one cell, which divides into two, four, eight into a human of a few billion cells. Almost all cells in an adult human skin cells, liver cells, eye lens cells, nerve cells, insulin-producing cells etc are highly specialized to perform a specific function. They are no longer capable of taking on another task: when a skin cell divides, you get more skin cells. During the growth from an embryo to an adult human, the cells become more and more specialized ("differentiated", biologists say).

Cancer cells are an exception to that rule: they are much less specialized, and feel at home in different places in the body. Researchers have long believed that cells must take the last step in their specialization to be better protected from turning into cancer cells. However, this was not proven in a living organism.

Suppressing cancer

Wouter Bossuyt from the Group of Bassem Hassan and their fellow VIB researchers at K.U.Leuven, now demonstrate with fruit flies that master control genes steering the specialization step indeed inhibit tumor formation. The specific example the VIB scientists used, are the ones biologists call the Atonal genes. These genes are very similar to each other in all species, from flies to humans.

With mice, and in collaboration with colleagues from the United States, they showed that loss of one of those genes, Atonal homolog 1 or ATOH1, causes colon cancer. The gene regulates the last step in the specialization to epithelial cell of the colon. Humans with colon cancer frequently have an inactivated ATOH1 gene, the researchers observed.


The researchers could in a test tube reactivate the gene in human colon cancer cells. The tumor cells stopped growing and committed suicide. Since they were able to switch the gene on with a reasonably simple chemical, this opens possibilities to one day perhaps switch the gene back on in living patients. It will be very important in the future to study in detail how exactly ATOH1 does performs its anti-cancer job


Contact: Sooike Stoops
VIB (the Flanders Institute for Biotechnology)

Related biology technology :

1. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
2. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. Computer predicts anti-cancer molecules
5. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
6. ARIUS presents new findings for anti-cancer antibody programs at AACR
8. Vaccinogens New Anti-Cancer Vaccine Commercially Available in Europe This Year
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. Egenix Licenses Harvard Anti-Cancer Platform
11. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Post Your Comments:
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is ... it is bound to proteins, copper is also toxic to cells. With a ... Polytechnic Institute (WPI) will conduct a systematic study of copper in the bacteria ...
(Date:11/24/2015)... ... , ... This fall, global software solutions leader SAP and AdVenture Capital brought ... pitch their BIG ideas to improve health and wellness in their schools. , Now, ... the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):